But such testing has been scattershot. Less than 1% of positive specimens in the U.S. are being sequenced to determine whether they have worrisome mutations. Other countries do better Britain sequences about 10% meaning they can more quickly see threats coming at them. That gives them greater opportunity to slow or stop the problem, whether through more targeted contact tracing, possible adjustments to the vaccine, or public warnings. CDC officials say variants have not driven recent surges in overall U.S. cases. But experts worry that what s happening with variants is not clear and say the nation should have been more aggressive about sequencing earlier in the epidemic that has now killed over 450,000 Americans.
US rushes to catch up in the race to detect mutant viruses
by Mike Stobbe And Marion Renault, The Associated Press
Posted Feb 4, 2021 10:57 am EDT
Last Updated Feb 4, 2021 at 10:58 am EDT
NEW YORK Despite its world-class medical system and its vaunted Centers for Disease Control and Prevention, the U.S. fell behind in the race to detect dangerous coronavirus mutations. And it’s only now beginning to catch up.
The problem has not been a shortage of technology or expertise. Rather, scientists say, it’s an absence of national leadership and co-ordination, plus a lack of funding and supplies for overburdened laboratories trying to juggle diagnostic testing with the hunt for genetic changes.
Coronavirus variants: US researchers race to catch up chicagotribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chicagotribune.com Daily Mail and Mail on Sunday newspapers.
Fox News medical contributor Dr. Marc Siegel answers parents’ questions on whether it’s safe to return to in-person learning amid the coronavirus pandemic.
Despite its world-class medical system and its vaunted Centers for Disease Control and Prevention, the U.S. fell behind in the race to detect dangerous coronavirus mutations. And it’s only now beginning to catch up.
The problem has not been a shortage of technology or expertise. Rather, scientists say, it’s an absence of national leadership and coordination, plus a lack of funding and supplies for overburdened laboratories trying to juggle diagnostic testing with the hunt for genetic changes.